A 3D printing-based postoperative drug slow-release stent and its preparation method

A 3D printing and medicine technology, applied in the field of medicine, can solve the problems of many adverse reactions, allergies, low bioavailability, etc., and achieve the effect of simple preparation method and equipment requirements, high biocompatibility, and high biocompatibility

Active Publication Date: 2020-08-07
云智前沿科技发展(深圳)有限公司
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Due to the large side effects of anti-tumor drugs, while killing tumor cells, it will cause damage to normal tissue cells in the body, reduce human immunity, and is not conducive to the recovery of tumor patients. Therefore, it is necessary to select a suitable drug carrier for anti-tumor drugs. Embedding, to eliminate or reduce the harm to the human body
Since antineoplastic drugs are generally poor in water solubility, it is generally necessary to add a variety of and a large amount of organic solvents to aid in dissolution. more, resulting in redness, erythema, allergies, itching, etc., and the quality stability of the preparation is poor, and the bioavailability is low

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0023] The preparation method of the postoperative drug slow-release stent based on 3D printing of the present invention includes the steps of dissolving gliadin, dissolving the drug to be embedded, and printing and forming. The specific steps are as follows:

[0024] A. Dissolving gliadin: Add cereal gliadin into ethanol aqueous solution and stir until the solution is uniform and transparent to obtain gliadin solution;

[0025] B. The drug to be embedded is dissolved: the drug to be embedded is added to the above prolamin solution and stirred until the solution is uniform and transparent to obtain a prolamin mixture;

[0026] C. Printing and forming: the above prolamin mixture is put into the liquid storage chamber of the 3D printing device, and the 3D printing device prints the postoperative drug sustained release stent according to the 3D model data of the postoperative drug sustained release stent required by the patient.

[0027] The step A is stirred and dissolved at nor...

Embodiment 1

[0035] 1. Under normal temperature and pressure, weigh 1g of zein, dissolve it in 30ml of 80% ethanol-water solution, stir it ultrasonically for 10-12min until the solution is uniform and transparent, and prepare about 33mg / ml of zein solution;

[0036] 2. Under normal temperature and pressure, weigh 0.1g of doxorubicin, dissolve it in the above-mentioned zein solution, and stir it ultrasonically for 10-12 minutes until the solution is uniform and transparent, and prepare doxorubicin of about 3.3mg / ml Zein mixture;

[0037] 3. Put the above-mentioned doxorubicin zein mixture into the liquid storage chamber of the 3D printing device, and the 3D printing device prints the postoperative drug sustained release stent according to the 3D model data of the postoperative drug sustained release stent required by the patient .

Embodiment 2

[0039]1. Under normal temperature and pressure, weigh 10g of wheat prolamin, dissolve it in 30ml of 84% ethanol-water solution, and stir it ultrasonically for 10 to 12 minutes until the solution is uniform and transparent, and prepare about 330mg / ml of wheat prolamin solution;

[0040] 2. Under normal temperature and pressure, weigh 0.5g of etoposide, dissolve it in the above-mentioned wheat prolamin solution, and stir it ultrasonically for 10-12 minutes until the solution is uniform and transparent, and prepare etoposide wheat alcohol of about 16.7mg / ml Protein-dissolving mixture;

[0041] 3. Put the above etoposide wheat prolamin mixture into the liquid storage chamber of the 3D printing device, and the 3D printing device prints the postoperative drug sustained release stent according to the 3D model data of the postoperative drug sustained release stent required by the patient;

[0042] 4. The above-mentioned printed postoperative drug sustained release stent is irradiated...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
pore sizeaaaaaaaaaa
Login to view more

Abstract

The invention discloses a postoperation drug sustained release support based on 3D printing and a preparation method thereof. The sustained release support is prepared from cereal alcohol-soluble protein, drug to be embedded and an ethanol water solution mixed alcohol-soluble protein mixed solution, wherein the concentration of the cereal alcohol-soluble protein in the mixed solution is 1 to 330mg / ml, the concentration of the drug to be embedded is 0.1 to 33mg / ml, and the mixed solution is 3D printed to obtain the postoperation drug sustained release support. The preparation method comprises an alcohol-soluble protein dissolving step of taking cereal alcohol-soluble protein, adding into an ethanol water solution and stirring until the solution is even and transparent; a drug to be embedded dissolving step of taking the drug to be embedded, adding into the alcohol-soluble protein solution and stirring until the solution is even and transparent; a postoperation drug sustained release support printing and forming step of feeding the alcohol-soluble protein mixed solution into 3D printing equipment to print and obtain the postoperation drug sustained release support according to a 3D model of the postoperation drug sustained release support. The postoperation drug sustained release support disclosed by the invention has the characteristics of simple method, high accuracy, quick speed, low cost, no toxic and side effects, good biocompatibility and long sustained release time.

Description

technical field [0001] The invention belongs to the technical field of medicines, and specifically relates to a 3D printing-based postoperative drug slow-release stent with simple methods, high precision, fast speed, low cost, no toxic and side effects, good biocompatibility, and long slow-release time. its preparation method. Background technique [0002] Controlled drug release is to use natural or polymer compounds as drug carriers to control the release rate of drugs in the human body, so that drugs can be released slowly within a certain time range and speed to achieve the purpose of treating a certain disease. Compared with conventional release, the advantages of controlled release include (1) it can effectively control the concentration of the drug, avoiding sudden highs and lows and the occurrence of toxic and side effects, (2) the utilization rate of the drug can reach 80-90%, compared with The regular release is high, (3) the release location is close to the sourc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07K14/425A61L31/04A61L31/16B33Y80/00
CPCA61L31/047A61L31/16A61L2300/416B33Y80/00C08L89/00
Inventor 孙洪亮仇乐杜鑫石绮君刘爽贺婷婷张莹莹
Owner 云智前沿科技发展(深圳)有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products